DNMT3A and acute myeloid leukemia: The presence of unfavorable karyotype (P = 0.013) and randomization in the control arm (P = 0.007) were retained as significantly associated with higher CIR in the whole cohort, while, only the presence of MLL-PTD (P = 0.014) and DNMT3A mutations (P = 0.010) independently predicted higher CIR in CN-AML patients (Table 3).